tetano
Editor, Senior Moderator
Int J Cancer
. 2020 Jul 19.
doi: 10.1002/ijc.33213. Online ahead of print.
Cancer associates with risk and severe events of COVID-19: A systematic review and meta-analysis
Yehong Tian[SUP] 1 [/SUP], Xiaowei Qiu[SUP] 1 [/SUP], Chengxiang Wang[SUP] 1 [/SUP], Jianxin Zhao[SUP] 1 [/SUP], Xin Jiang[SUP] 1 [/SUP], Wenquan Niu[SUP] 2 [/SUP], Jinchang Huang[SUP] 1 [/SUP], Fengyu Zhang[SUP] 3 4 [/SUP]
Affiliations
Abstract
Evidence is mounting to indicate that cancer patients may have more likelihood of having coronavirus disease 2019 (COVID-19) but lack consistency. A robust estimate is urgently needed to convey appropriate information to the society and the public, in the time of ongoing COVID-19 pandemic. We performed a systematic review and meta-analysis through a comprehensive literature search in major databases in English and Chinese, and two investigators conducted publication selection and data extraction independently. A meta-analysis was used to obtain estimates of pooled prevalence of cancer in patients with COVID-19 and determine the association of cancer with severe events, after assessment of potential heterogeneity, publication bias, and correction for the estimates when necessary. Total 38 studies comprising 7,094 patients with COVID-9 were included; the pooled prevalence of cancer was estimated at 2.3% (95% confidence limit[CL] [0.018, 0.029]; p<0.001) overall and 3.2% (95% CL [0.023,0.041]; p<0.001) in Hubei province; the corresponding estimates were 1.4% and 1.9% after correction for publication bias; cancer was significantly associated with the events of severe cases (odds ratio [OR]=2.20, 95% CL[1.53, 3.17]; p<0.001) and death (OR=2.97, 95% CL[1.48, 5.96]; p=0.002) in patients with COVID-19, there was no significant heterogeneity and a minimal publication bias. We conclude that cancer comorbidity is associated with the risk and severe events of COVID-19; special measures should be taken for individuals with cancer. This article is protected by copyright. All rights reserved.
. 2020 Jul 19.
doi: 10.1002/ijc.33213. Online ahead of print.
Cancer associates with risk and severe events of COVID-19: A systematic review and meta-analysis
Yehong Tian[SUP] 1 [/SUP], Xiaowei Qiu[SUP] 1 [/SUP], Chengxiang Wang[SUP] 1 [/SUP], Jianxin Zhao[SUP] 1 [/SUP], Xin Jiang[SUP] 1 [/SUP], Wenquan Niu[SUP] 2 [/SUP], Jinchang Huang[SUP] 1 [/SUP], Fengyu Zhang[SUP] 3 4 [/SUP]
Affiliations
- PMID: 32683687
- DOI: 10.1002/ijc.33213
Abstract
Evidence is mounting to indicate that cancer patients may have more likelihood of having coronavirus disease 2019 (COVID-19) but lack consistency. A robust estimate is urgently needed to convey appropriate information to the society and the public, in the time of ongoing COVID-19 pandemic. We performed a systematic review and meta-analysis through a comprehensive literature search in major databases in English and Chinese, and two investigators conducted publication selection and data extraction independently. A meta-analysis was used to obtain estimates of pooled prevalence of cancer in patients with COVID-19 and determine the association of cancer with severe events, after assessment of potential heterogeneity, publication bias, and correction for the estimates when necessary. Total 38 studies comprising 7,094 patients with COVID-9 were included; the pooled prevalence of cancer was estimated at 2.3% (95% confidence limit[CL] [0.018, 0.029]; p<0.001) overall and 3.2% (95% CL [0.023,0.041]; p<0.001) in Hubei province; the corresponding estimates were 1.4% and 1.9% after correction for publication bias; cancer was significantly associated with the events of severe cases (odds ratio [OR]=2.20, 95% CL[1.53, 3.17]; p<0.001) and death (OR=2.97, 95% CL[1.48, 5.96]; p=0.002) in patients with COVID-19, there was no significant heterogeneity and a minimal publication bias. We conclude that cancer comorbidity is associated with the risk and severe events of COVID-19; special measures should be taken for individuals with cancer. This article is protected by copyright. All rights reserved.